Integrated Cannabis Company Inc. (OTCQB:ICNAF)(CSE:ICAN)| Breaking News Alert for (OTCQB:ICNAF)(CSE:ICAN) Company

Integrated Cannabis Company, Inc. Signs Distribution Agreement with Empower Clinics, Inc.

VANCOUVER, British Columbia, - September 20, 2018 -- Integrated Cannabis Company Inc. (OTCQB:ICNAF) (CSE:ICAN) (the “Company” or “Integrated Cannabis”) is pleased to announce the completion of a Letter of Intent (LOI) to distribute X-SPRAYS™ products throughout the clinics and doctors’ offices of Empower Clinics Inc. (CSE: EPW; FRA: 8EC) (“Empower”), a leading owner and operator of medical cannabis and wellness clinics in the United States (US).

The companies have recently engaged with their marketing and distribution teams to streamline the logistics of rolling out new products in the Empower clinics. Integrated Cannabis will distribute all of its CBD-infused X-SPRAYS™ including; CBD, Sleep, Recover, Libido and Energy throughout the Empower ecosystem.

“We believe this milestone marks another significant move for distribution of X-SPRAYS™ in key markets across the United States. In addition, we believe this alliance will help increase awareness from credible sources about alternative

treatments for those struggling with opioid addiction, pain, anxiety, sleep issues and people seeking overall well-being,” said Mr. John Knapp, CEO of Integrated Cannabis. The Company expects to sign a definitive agreement with Empower in the coming weeks.

“We are very excited about our partnership with X-SPRAYS as we believe it brings leading technology and treatment for the most common conditions our patients face. X-SPRAYS state of the art product formulations and unique metered dosage help consistently deliver a world class product,” said Mr. Craig Snyder, CEO of Empower.

As of August 31, Empower has more than 25,000 patients under care across 15 locations with medical cannabis treatments in Oregon, Washington and Illinois. The patient base in Oregon represents approximately one-third of the state’s total medical card issuance. In addition, Empower has an historical patient database of more than 120,000 in the two states.

On September 12, Empower announced the opening of its flagship Chicago clinic. In Illinois, the company seeks to expand its operations and achieve a leadership position as it executes on parallel national clinic and product strategies. There is currently an opioid epidemic in the United States and the company’s announced Chicago facility closely followed the endorsement by Illinois Governor Bruce Rauner of medical cannabis as a frontline treatment and alternative for patients with a new statewide measure he signed into law on Aug 28.

ABOUT EMPOWER
Empower is a leading owner and operator of medical cannabis and wellness clinics, as well as a developer of medical products in the US, focused on enabling individuals to improve and protect their health. The company provides treatment solutions through its physician-staffed clinics that are focused on education, data, and efficacy. Empower is a recognized leader and the first choice for patients seeking quality experience and improved health.

About Integrated Cannabis Company
Integrated Cannabis Company, Inc. is comprised of dedicated scientists and product engineers who are passionate about health and creating health and lifestyle products utilizing advanced delivery systems and formulations. For more information, please visit the company’s website at: www.x-sprays.com.

ON BEHALF OF THE BOARD
“John Knapp”
Chief Executive Officer
For further information, please contact:
Telephone: 778-403-3358
Email: info@cnrpmining.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

VANCOUVER, British Columbia, - September 13, 2018 -- Integrated Cannabis Company Inc. (OTCQB:ICNAF) (CSE:ICAN) (the “Company” or “Integrated Cannabis”) is pleased to announce the completion of a market ready Tetrahydrocannabinol (THC)-infused spray product and the required licensure for manufacturing of the product in Colorado.

Over the past ten months the Company has engaged and worked with contractors, consultants and various state and municipal regulators in order to successfully gain licensing and approvals for facilities that manufacture CBD- and THC-infused products in the State of Colorado.

The THC product employs the same nanotechnology used to enhance the CBD-infused X-SPRAYS™, resulting in higher bioavailability and faster uptake versus capsules or powder. The Company continues to enhance the flavor profiles in order to find an optimal formula.

“We are pleased to be adding THC products to our proprietary line of sprays and plan to launch via distribution in Colorado beginning in Q4 and shall pursue other legal markets thereafter,” said Mr. John Knapp, CEO of Integrated Cannabis.

To best demonstrate the Company’s activities in the Manufacturer of Infused Products (MIP) area, a chronological outline follows:

• Completed the build out of a commercial kitchen adjacent to a licensed Medical and Recreational extraction lab
• Completed Process Validation with the Colorado Marijuana Enforcement Division (MED)
• Secured a high-quality CBD source from a supplier with Colorado Department of Public Health and Environment (CDPHE) Registration Certificate and Colorado Hemp License
• Received Shelf Stability approval to sell X-SPRAYS™ CBD formulation in Denver
• Received approval to sell CBD formulated products throughout all of Colorado
• Secured a high-quality THC source from a duly licensed Colorado Medical and Recreational extraction lab
• Received approval to sell THC formulated products throughout most of Colorado – only awaiting approval for City of Denver
• Submitted Shelf Stability application to sell X-SPRAYS™ THC formulation in Denver

About Integrated Cannabis Company
Integrated Cannabis Company, Inc. is comprised of dedicated scientists and product engineers who are passionate about health and creating health and lifestyle products utilizing advanced delivery systems and formulations. For more information, please visit the company’s website at: www.x-sprays.com.

ON BEHALF OF THE BOARD
“John Knapp”
Chief Executive Officer
For further information, please contact:
Eugene Beukman
Email: investors@cnrpmining.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
SOURCE: Integrated Cannabis Company Inc.

VANCOUVER, British Columbia, - September 6, 2018 -- Integrated Cannabis Company Inc. (OTCQB:ICNAF) (CSE:ICAN) (the “Company” or “Integrated Cannabis”) is pleased to provide a corporate update.

Commercial Stage Products: X-SPRAYS™
The Company’s X-SPRAYS™ product line consists of eight market ready orally ingested spray products that are highly effective for overall health and well-being as well as general lifestyle. Four products are available infused with hemp-based cannabidiol (CBD) and four products are formulated without a cannabidiol (CBD) infusion. The state of the art formulations are free from artificial flavours, artificial colours, sugar, starch, wheat, soy, gluten, eggs, salt and dairy. The sprays contain natural fruit and/or herbal flavours and are suitable for vegetarians and vegans. The products are highly bioavailable such that the active ingredients in the sprays are already fully dissolved, so the vitamins and minerals do not need to be further broken down once swallowed, but are immediately available for use by the body.

The X-SPRAYS™ product line is packaged in precise, metered dose and convenient spray tubes including a child-resistant version, both of which easily fit into a purse or pocket and are ideal for travel. The container protects the liquid from light and air, ensuring the quality and shelf life of the ingredients.

The full product offering is listed below in Table 1.0

Product Name	Product Description / Use
CBD	Stress relief, pain management
Sleep with CBD	Sleep aid, non habit forming
Focus	Mental clarity
Relief	General relief
Sleep	Sleep aid, non-habit forming
Recover	Anti-hangover
Energy	Energy boost
Libido	Aphrodisiac, enhance sexual vitality

X-SPRAYS™ Test Marketing
Online sales of the X-SPRAYS™ were initiated in late 2017 and have continued up to the present. These sales have been encouraging, considering the previously limited marketing budget, and the Company has seen numerous repeat customer orders which demonstrates product uptake and consumer affinity for the X-SPRAYS™.

In addition to Internet sales, the Company has test marketed selected products in two Medical Marijuana dispensaries in Colorado. These sales began in February 2018 and continue. Proceeds from these sales have been reinvested in Colorado marketing initiatives. The Company has learned, however, that marketing combined with in-store promotions can ge

nerate minimum sales in excess of 1 product per day in the retail environment. While this number is insignificant from a revenue perspective on a small scale retail distribution, it becomes significant when considering retail distribution outlets in the hundreds of locations. A single product selling only one unit per day in 100 stores could generate wholesale revenue in excess of tens of thousands of dollars per day. The Company has four products that are CBD infused, four non-CBD infused and a soon to be launched line of THC products that will have multiple SKU’s. With market testing complete, X-SPRAYS™ plans to roll out additional brick and mortar distribution throughout dispensaries, vape stores, gas stations, and convenience stores across the country.

Additionally, the Company intends to launch an aggressive online marketing campaign to drive sales through the utilization of traditional on-line channels and via established product influencers..

Acquisition Opportunities
“We are currently in the late stages of reviewing a short list of potential acquisition opportunities that would broaden our product offering from the existing X-SPRAYS line to potentially licensed Cannabis formulations in several US States,” said Mr. John Knapp, CEO of Integrated Cannabis Company. The Company will provide additional updates as required.

About Integrated Cannabis Company
Integrated Cannabis Company, Inc. is comprised of dedicated scientists and product engineers who are passionate about health and creating health and lifestyle products utilizing advanced delivery systems and formulations. For more information, please visit the company’s website at: www.x-sprays.com.

ON BEHALF OF THE BOARD
“John Knapp”
Chief Executive Officer and Director
For further information, please contact:
Email: investors@cnrpmining.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
SOURCE: Integrated Cannabis Company, Inc.

X-SPRAYS ANNOUNCES EXCLUSIVE DISTRIBUTION AGREEMENT WITH CONSUMER PACKAGED GOODS DISTRIBUTOR IN EUROPE

VANCOUVER, British Columbia, - November 30, 2017 -- CNRP Mining Inc. (OTCQB:CRPGF) (CSE:CND) (“CNRP” or the “Company”) is pleased to announce that X-SPRAYS has signed an exclusive distribution agreement with a national distributor of consumer packaged goods in Europe (the “Distributor”). Under the terms of the agreement the Distributor will supply X-SPRAYS products to the following countries: Germany, Austria and Switzerland.

The Distributor has a 10-year history and multiple existing retail channels, including pharmacies, drug stores and a robust online presence. X-SPRAYS products will be supplied leveraging the Distributor’s extensive network and this partnership provides X-SPRAYS with unique access to the European market. The Company will begin shipping products to the Distributor in early Q1-2018, pending necessary approvals. With a population exceeding 82 million people and federal insurance coverage for cannabis, Germany represents the world’s largest legal cannabis market.

“We are excited to have partnered with an established and recognized leader in the European consumer packaged goods marketplace. This agreement allows us to utilize an existing network with wide reach to immediately create a presence in the world’s largest federally legislated medicinal cannabis market,” said Mr. John Knapp, CEO of X-SPRAYS.

About X-SPRAYS

X-SPRAYS is comprised of dedicated scientists and product engineers who are passionate about health and creating the ultimate delivery system for optimal nutrition. The company has focused its efforts on creating a product line of oral sprays to deliver medicines, nutrients and vitamins. To date, X-SPRAYS has developed a novel line of 8 health care and life enhancement nutraceutical products focused on areas such as pain, energy, libido and sleep.

The Company’s product line is ready for commercialization with 8 novel sprays that include both hemp cannabidiol (CBD) and nutraceutical ingredients. X-SPRAYS intends to expand its product line to include cannabis tetrahydrocannabinol (THC) and additional CBD sprays. For more information, please visit the company’s website at: www.x-sprays.com.

ON BEHALF OF THE BOARD
"Randy Clifford"
Director
For further information, please contact:
Randy Clifford
Telephone: 780-466-6006
Email: info@cnrpmining.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

CNRP Mining Target X-SPRAYS Announces Start of Test Market for Products with Colorado Based Dispensary Group

VANCOUVER, British Columbia, - November 8, 2017 -- CNRP Mining Inc. (OTCQB:CRPGF) (CSE:CND) (“CNRP” or the “Company”) is pleased to announce that X-SPRAYS has launched a test market for two of its products with a group of Denver, Colorado based medical and recreational marijuana dispensaries. The test market is expected to last three months, after which the Company will provide an update on the sales and performance of the products. The products that will be subject to the test market are: 300mg CBD and Sleep with CBD.

About X-SPRAYS
X-SPRAYS is comprised of dedicated scientists and product engineers who are passionate about health and creating the ultimate delivery system for optimal nutrition. The company has focused its efforts in creating a product line of oral sprays to deliver medicines, nutrients and vitamins. To date, X-SPRAYS has developed a novel line of 8 health care and life enhancement nutraceutical products focused on enhancing pain relief, awareness, sleep, libido, energy and recovery.

VANCOUVER, British Columbia, - October 25, 2017 -- CNRP Mining Inc. (OTCQB:CRPGF) (CSE:CND) (“CNRP” or the “Company”) is pleased to announce that further to its press releases of July 21, 2017 and August 22, 2017 it has entered into a share exchange agreement dated October 24, 2017 (the “Definitive Agreement”) to acquire all of the issued and outstanding shares of 1127466 B.C. Ltd. which holds, through a wholly owned subsidiary, a world-wide, exclusive license for X-SPRAYS – a brand of stateof-the-art life-enhancement products administered via an optimal oral spray delivery system (the “Transaction”).

Pursuant to the terms of the Definitive Agreement, the Company will, upon closing of the Transaction, issue to X-SPRAYS shareholders an aggregate of 16,500,000 common shares in the capital of the Company (the “Payment Shares”) at a deemed price of CAD$0.30 per Payment Share. Additionally, up to 28,000,000 CNRP shares will be issuable upon certain commercial milestones being achieved by X-SPRAYS (the “Performance Shares”). The Payment Shares and the Performance Shares will be subject to escrow conditions and/or resale restrictions as required by applicable securities laws and the

policies of the Canadian Securities Exchange (the “CSE”).

The Transaction remains subject to certain closing conditions, including, obtaining all necessary approvals, including, approval of the respective boards, the approval of the CSE, and if applicable, shareholders of the Company. There can be no guarantees that the Transaction will be completed as proposed or at all. Subject to CSE approval, a finder’s fee of 1,650,000 common shares will be payable to an arm’s length party in connection with the Transaction. None of the Payment Shares or Performance Shares to be issued pursuant to the Transaction have been or will be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and any Payment Shares or Performance Shares issued pursuant to the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the Payment Shares to be issued pursuant to the Transaction under an exemption from the registration requirements of the U.S. Securities Act will be “restricted securities” as defined under Rule 144(a)(3) of the U.S. Securities Act and will contain the appropriate restrictive legend as required under the U.S. Securities Act.

About X-SPRAYS
X-SPRAYS is comprised of dedicated scientists and product engineers who are passionate about health and creating the ultimate delivery system for optimal nutrition. The company has focused its efforts in creating a product line of oral sprays to deliver medicines, nutrients and vitamins. To date, X-SPRAYS has developed a novel line of 8 health care and life enhancement nutraceutical products focused on enhancing pain relief, awareness, sleep, libido, energy and recovery.

The Company’s product line is ready for commercialization with 8 novel sprays that include both hemp cannabidiol (CBD) and nutraceutical ingredients (4 with CBD and 4 nutraceutical). X-SPRAYS intends to expand its product line to include cannabis Tetrahydrocannabinol (THC) and CBD sprays. For more information, please visit the company’s website at: www.x-sprays.com.

ON BEHALF OF THE BOARD
"Randy Clifford"
Director
For further information, please contact:
Randy Clifford
Telephone: 780-466-6006
Email: info@cnrpmining.com

The CSE does not accept responsibility for the adequacy or accuracy of this release. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

CNRP Mining Announces Closing of $3,000,000 Private Placement and Amendments to Previously Closed Offerings

VANCOUVER, British Columbia, - Sept. 26, 2017 -- CNRP Mining Inc. (OTCQB:CRPGF) (CSE:CND) (“CNRP” or the “Company”) is pleased to announce that it has now closed its previously announced (see press releases dated July 21, 2017 and August 22, 2017) non-brokered private placement offering (the “Offering”). In connection with the Offering, the Company issued 10,000,000 common shares in the capital of the Company (a “Share”) at a price of $0.30 per Share for gross proceeds of $3,000,000.

In connection with the Offering, the Company has paid eligible finders a cash commission in the aggregate amount of $86,631.96 being 8% of the gross proceeds from the sale of Shares to purchasers introduced by the finders, as well as issued an aggregate of 288,773 finders’ warrants (“Finders’ Warrants”), which is equal to 8% of the number of Shares sold to purchasers introduced by the finders. Each Finders’ Warrant entitles the finder to acquire a Share at an exercise price of $0.40 per Share until September 26, 2018.

All securities issued in connection with the Offering are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation expiring on January 27, 2017. The net proceeds from the Offering are expected to be used to fund the Company’s acquisition of X-Sprays (see press release dated August 22, 2017) and for general corporate purposes.

Additionally, the Company reports that the terms of its previously closed non-brokered private placements have been amended.

Specifically, on June 13, 2017, the Company completed a non-brokered private placement of units (“Units”) at a price of $0.115 per Unit for gross proceeds of $1,036,437.50. Each Unit was comprised of one Share and three-quarters of one transferable common share purchase warrant (each whole warrant, a “Warrant”), with each Warrant exercisable into one additional Share at a price of $0.15 until June 13, 2018. An aggregate of 9,012,500 Shares and 6,759,375 Warrants were issued in connection with this offering. The price per Unit has been voluntarily adjusted by the subscribers from $0.115 to $0.30 (“Adjusted Unit”) and each warrant will be exercisable at a price of $0.30 per Share rather than $0.15 (“Adjusted Warrant”). In addition, some securities issued in connection with this offering have been cancelled. In total, the Company issued 3,731,950 Adjusted Units at a price of $0.30 per Adjusted Unit for gross proceeds of $1,119,585. An aggregate of 3,731,950 Shares and 2,798,955 Adjusted Warrants were issued.

In addition, On July 14, 2017, the Company completed a non-brokered private placement of Shares at a price of $0.20 per Share for gross proceeds of $600,000. An aggregate of 3,000,000 Shares were issued in connection with this offering. The price per Share has been voluntarily adjusted by the subscribers from $0.20 per Share to $0.30 per Share. In addition, some securities issued in connection with this offering have been cancelled. In total, the Company issued 1,683,329 Shares at a price of $0.30 per Share for gross proceeds of $504,998.70.

ON BEHALF OF THE BOARD

"Randy Clifford"
Director

For further information, please contact:
Randy Clifford
Telephone: 780-466-6006
Email: info@cnrpmining.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, included herein, including statements regarding the proposed share consolidation, the proposed shares for debt settlement transactions and the creation of a new control person, are forward-looking information. Forward-looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions or are those which, by their nature, refer to future events. Although the Company believes that such statements are reasonable, there can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The Company cautions investors that any forward-looking information disclosed by the Company is not a guarantee of future performance, and that actual results may differ materially from those in forward-looking information. Accordingly, readers should not place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Source: CNRP Mining

CNRP Mining Inc. Provides Update on X-SPRAYS Acquisition and $3,000,000 Private Placement

VANCOUVER, British Columbia, - August 23, 2017 -- CNRP Mining Inc. (OTCQB:CRPGF) (CSE:CND) (“CNRP” or the “Company”) is pleased to announce that further to the Company’s press release on July 21, 2017 and in conjunction with its non-binding letter of intent (the “LOI”) to acquire X-SRAYS (the “Transaction”), it has advanced USD $300,000 to X-SPRAYS. Furthermore, CNRP anticipates signing a definitive agreement for the acquisition in September 2017.

Through the Transaction CNRP will acquire all of the issued and outstanding shares of 1127466 B.C. Ltd. which holds, through a wholly owned subsidiary, a world-wide, exclusive license for X-SPRAYS – a brand of state-of-the-art life-enhancement products administered via an optimal oral spray delivery system.

The Transaction remains subject to certain closing conditions, including, completion of due diligence, the negotiation and signing of a definitive agreement and obtaining all necessary approvals, including, approval of the respective boards, the approval of the CSE, and if applicable, shareholders of the Company. There can be no guarantees that the Transaction will be completed as proposed or at all.

Private Placement
In connection with the Transaction, the Company is also pleased to announce that it intends to close its previously announced non-brokered private placement offering of up to 10,000,000 shares (the “Shares”) at a price of $0.30 per Share for gross proceeds of up to $3,000,000 (the “Offering”) in early September 2017.

Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the CSE. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions.

The Company confirms that it has no relationship with MarijuanaStocks.com and did not solicit or pay a fee to them for the recent article they posted touting CNRP Mining Inc.

ON BEHALF OF THE BOARD
“Randy Clifford”
CEO

For further information, please contact:
Randy Clifford
Telephone: 780-466-6006
Email: info@cnrpmining.com

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

For further information, please contact:
Randy Clifford
Telephone: 780-466-6006
Email: info@cnrpmining.com

Source: CNRP Mining

CANADIAN MINING CORP. ANNOUNCES CLOSING OF OVER-SUBSCRIBED NON-BROKERED PRIVATE PLACEMENT

VANCOUVER, British Columbia, - August 3, 2017 -- CNRP Mining Inc. (OTC:CRPGF) (CSE:CND) (“CNRP” or the “Company”) further to its news release of July 5, 2017, has closed a non-brokered private placement for 8,798,944 units at a price of 25 cents per unit to raise gross proceeds of $2,199,736. Due to demand, the offering was increased from $2-million in gross proceeds.

Each unit will consist of one common share and one non-transferable common share purchase warrant. Each common share purchase warrant is exercisable for one additional common share of the company at a price of $1 for a period of two years from the date of issue.

Of particular interest with this offering is that all participants of the financing have signed a voluntary pooling agreement

that subjects the shares acquired, and any shares acquired on exercise of the share purchase warrants, to an eight-month staged release of 50 per cent of the shares becoming free trading every four months.

The company paid cash finders' fees of $147,345.52 and issued 365,820 share purchase warrants to certain qualified finders in connection with the offering. Each finder's warrant is exercisable into one common share of the company at a price of $1 per share for a period of two years from the date of issuance.

Proceeds from the offering will be used to advance the company's operations and general working capital, including potential acquisitions, marketing, corporate accounting and geological services.

The offering is subject to the approval of the TSX Venture Exchange, and all securities issued thereunder will be subject to a minimum of a four-month-and-one-day hold period under applicable securities laws.

We seek Safe Harbor.

For further information, please contact:
Randy Clifford
Telephone: 780-466-6006
Email: info@cnrpmining.com

Source: CNRP Mining

VANCOUVER, British Columbia, July 21, 2017 (GLOBE NEWSWIRE) -- CNRP Mining Inc. (OTC:CRPGF) (CSE:CND) (“CNRP” or the “Company”) is pleased to announce that it has entered into non-binding letter of intent (the “LOI”) to acquire (the “Transaction”) all of the issued and outstanding shares of 1127466 B.C. Ltd. which holds, through a wholly owned subsidiary, a world-wide, exclusive license for X-SPRAYS – a brand of state-of-the-art life-enhancement products administered via an optimal oral spray delivery system.

About X-SPRAYS
X-SPRAYS is comprised of dedicated scientists and product engineers who are passionate about health and creating the ultimate delivery system for optimal nutrition. The company has focused its efforts in creating a product line of oral sprays to deliver medicines, nutrients and vitamins. To date, X-SPRAYS has developed a novel line of 8 health care and life enhancement nutraceutical products focused on enhancing pain relief, awareness, sleep, libido, energy and recovery.

The Company’s product line is ready for commercialization with 8 novel sprays that include both hemp cannabidiol (CBD) and nutraceutical ingredients (4 with CBD and 4 nutraceutical). X-SPRAYS intends to expand its product line to include cannabis Tetrahydrocannabinol (THC) and CBD sprays. For more information, please visit the company’s website at: www.x-sprays.com.

Letter Agreement
Pursuant to the terms of the Letter Agreement, the Company will, upon closing of the Transaction, issue to X-SPRAYS shareholders an aggregate of 14,666,667 common shares in the capital of the Company (the “Payment Shares”) at a deemed price of CAD$0.30 per Payment Share. Additionally, up to 20,000,000 CNRP Shares will be issuable upon certain commercial milestones being achieved by X-SPRAYS. The Payment Shares will be subject to escrow conditions and/or resale restrictions as required by applicable securities laws and the policies of the Canadian Securities Exchange (the “CSE”).

The Transaction remains subject to certain closing conditions, including, completion of due diligence, the negotiation and signing of a definitive agreement and obtaining all necessary approvals, including, approval of the respective boards, the approval of the CSE, and if applicable, shareholders of the Company. There can be no guarantees that the Transaction will be completed as proposed or at all.

Private Placement
In connection with the Transaction, the Company is also pleased to announce that it intends to complete a non-brokered private placement offering of up to 10,000,000 shares (the “Shares”) at a price of $0.30 per Share for gross proceeds of up to $3,000,000 (the “Offering”).

In connection with the Offering, the Company may pay a finder’s fee on the Offering within the amount permitted by the policies of the CSE.

Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the CSE. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions.

None of the Payment Shares to be issued pursuant to the Transaction or securities issued pursuant to the Offering have been or will be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and any Payment Shares issued pursuant to the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the Payment Shares to be issued pursuant to the Transaction under an exemption from the registration requirements of the U.S. Securities Act will be “restricted securities” as defined under Rule 144(a)(3) of the U.S. Securities Act and will contain the appropriate restrictive legend as required under the U.S. Securities Act.

ON BEHALF OF THE BOARD
“Randy Clifford”
CEO

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

For further information, please contact:
Randy Clifford
Telephone: 780-466-6006
Email: info@cnrpmining.com

Source: CNRP Mining

-------------------------------------------------------------------
About Integrated Cannabis Company Inc.:

About
Our company is comprised of dedicated scientists and product engineers who are passionate about health and creating the ultimate delivery system for optimal nutrition. The ongoing vision comes from Dr. Clive Spray, our founder. Dr. Spray remains as involved in formulations and manufacturing as the day he started this process 17 years ago.

Our dedicated research and development explores ways to incorporate the best of nutritional science into our products, bringing nutrition into the 21st century. Our people are passionate about making a difference, and our products are the result of that passion.

The Science:

- International Journal of Pharmacy & Life Sciences: Intra Oral Sprays- An Overview

Over the last three decades, intraoral dosage forms have been evolving as an acceptable and in some cases as the preferred, alternative to conventional tablets and capsules. Among them, Oral sprays are the fastest, most effective and comfortable way to take medicines, nutrients, minerals and vitamins. They have been acquiring important position in the market by overcoming previously encountered administration problems and contributing to extension of patent life.

Oral sprays have the unique property of rapidly releasing the drug in the oral cavity, thus obviating the requirement of water during administration. Therefore, these dosage forms have lured the market for a certain section of the patient population which includes dysphagic, bed ridden, and psychic, geriatric patients. This article focuses on the transmucosal view , spray formulation aspects , advances made so far in the field oral sprays and patented technologies.

- A Multi Center Trial: Studies on the response of nitroglycerin oral spray compared with sublingual tablets for angina pectoris patients with dry mouth.

Abstract: Nitroglycerin (glyceryl trinitrate, CAS 55-63-0, NTG) administered with an oral spray may be more effective in relieving anginal pain than sublingual tablets especially when the patient’s mouth is dry. In this study, the effect of a NTG oral spray (Myocor Spray) on exercise-induced angina was compared with that of a sublingual tablet in relation to the oral dryness. In 17 patients with effort angina, graded bicycle exercise was performed twice at an interval of one week.

Exercise was discontinued upon the onset of moderate anginal pain. Immediately after exercise, the oral dryness was evaluated by touching the tip of the tongue with a blotting paper for a moment. Then, 0.3 mg of NTG was administered by either a squirt of spray or a sublingual tablet in a randomized crossover fashion. Exercise results were reproducible between two exercise tests. According to the extent of the wet area of the blotting paper, the subjects were divided into two groups.

In 7 patients of the wet group, the remission times of chest pain and ST segment depression were not significantly different by the formulation of NTG. In 10 patients of the dry group, however, both chest pain and ST depression more rapidly recovered with use of the oral spray (p < 0.05 and p < 0.05, respectively). These results strongly suggest that the NTG oral spray is superior to the sublingual tablet in relieving anginal attacks, when the oral wetness is decreased.

About the Products:

- Highly bioavailable

The active ingredients in our fine mist sprays are already fully dissolved or dispersed into the spray solution. This means the important vitamins and minerals do not need to be broken down once swallowed, but are immediately available for use by the body

- Simply Superior

We know that using oral spray nutritional supplements is simply superior to taking pills or capsules. Very few of us enjoy swallowing pills, and many are not physically able to. The oral spray delivery system is the convenient, pleasant-tasting alternative.

- State of the art formulations

We have taken great care to create excellence. Our formulas are free of: artificial flavors, artificial colors, sugar, starch, wheat, soy, gluten, eggs, salt and dairy. Our sprays contain natural fruit or mint flavors and are suitable for vegetarians.

- Convenience

The spray tube easily fits in your purse, pocket, or briefcase. Convenient use of the spray without the need for a glass of water to take your supplements. The spray tubes are perfect for travel. The container we use protects the liquid from light and air, keeping the ingredients potent.

- Reliable dosage

Each oral spray gives a precise, metered dose of product with every pump.

- 30 Doses in Every Tube

Each tube of X-SPRAYS ™ products contains a 30 day supply when used as suggested which is 8 sprays every day.

Frequently Asked Questions
Q: Why are your products sprays?

A: We believe that using oral spray nutritional supplements is simply superior to taking pills or capsules. Very few of us enjoy swallowing pills, and many are not physically able to. The oral spray delivery system is the convenient, pleasant-tasting alternative.

Q: What is the tube made from?

A: X-SPRAYS products are packaged in aluminum tubes. The interior of the tube is lined with a coating to ensure that the liquid vitamins do not come into direct contact with the aluminum of the can.

Q: How do I use the products?

A: Each X-Sprays product is an oral spray nutritional supplement. To use the product:

Gently shake the tube
Spray into the mouth preferably onto the inside of the cheeks, hold in the mouth and then swallow
Spray a total of 8 sprays per day to receive the recommended dose as indicated on the label.

Q: How should I store the product?

A: X-Sprays products should be stored at room temperature in an upright position.

Q: Are your products tested on animals?

A: No

Q: Are X-SPRAYS products suitable for vegetarians?

A: Yes, there are no animal products or ingredients derived from animals in our products.

Q: How long does one tube of X-SPRAYS vitamins last?

A: Each tube (vial) contains a one-month (30 day) supply when used as suggested (8 sprays per day).

Q: What about allergens in the products?

A: At X-SPRAYS we use no artificial flavors or colors, and no starch, wheat, soy, gluten, eggs, salt, or dairy.

Q: What do you use to flavor the products?

A: X-SPRAYS products are flavored with natural fruits and mints. The products are sweetened with either xylitol or steviol glycosides (stevia leaf extract).

SOURCE: http://www.x-sprays.com/

Integrated Cannabis Company Inc. (OTCQB:ICNAF) (CSE:ICAN) Breaking News - September 20, 2018

Disclaimer